Dartmouth regimen

None

A nonsteroidal antiestrogenic agent with combined partial-estrogen-agonist activity. FDA approved uses on breast cancer and risk reduction for women with high risk of developing breast cancer.

Literature shows that Tamoxifen is being prescribed for recurrent/relapsed ovarian cancer.

This drug should be coded

None

FDA approved on Hodgkin's lymphoma, and metastatic melanoma.

This drug should be coded

None

An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.

This drug should be coded

None

Phase I FDA approved uses on brain tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma. Guilford Pharmaceuticals.(nitrosourea) (alkylating agent)

This drug should be coded